Headlines about Viewray (NASDAQ:VRAY) have trended somewhat negative on Tuesday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viewray earned a media sentiment score of -0.06 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.1538107685476 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news articles that may have effected Accern’s scoring:
- Stock’s Volatility Analysis – ViewRay Inc (NASDAQ: VRAY) (stockspen.com)
- Price to Earnings Ratio to Track – ViewRay Inc (NASDAQ: VRAY) (stocksmarketcap.com)
- Viewray (VRAY) Upgraded to “Sell” by BidaskClub (americanbankingnews.com)
- Time To Buy? Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) and ViewRay, Inc. (NasdaqGM:VRAY)’s ROIC Under … (concordiareview.com)
- Hot Stock’s Highlights – ViewRay Inc (NASDAQ: VRAY) (stocksmarketcap.com)
A number of equities research analysts have recently weighed in on the company. BidaskClub upgraded Viewray from a “strong sell” rating to a “sell” rating in a research report on Friday. Cantor Fitzgerald set a $13.00 price objective on Viewray and gave the company a “buy” rating in a report on Monday, January 8th. B. Riley assumed coverage on Viewray in a report on Thursday, February 8th. They issued a “buy” rating and a $13.50 price objective for the company. Finally, Mizuho reiterated a “buy” rating and issued a $12.00 price objective on shares of Viewray in a report on Tuesday, January 9th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $11.58.
NASDAQ VRAY traded down $0.04 on Tuesday, reaching $7.05. The company had a trading volume of 331,883 shares, compared to its average volume of 641,828. The company has a market capitalization of $523.01, a PE ratio of -6.79 and a beta of 0.64. The company has a current ratio of 2.18, a quick ratio of 1.84 and a debt-to-equity ratio of 22.47. Viewray has a 52 week low of $4.40 and a 52 week high of $10.64.
Viewray (NASDAQ:VRAY) last released its quarterly earnings data on Monday, March 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.13). The company had revenue of $19.90 million during the quarter, compared to analyst estimates of $21.23 million. The firm’s quarterly revenue was up 23.6% on a year-over-year basis. sell-side analysts predict that Viewray will post -0.71 earnings per share for the current fiscal year.
In related news, insider James F. Dempsey sold 75,243 shares of the company’s stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $7.57, for a total value of $569,589.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 62.81% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://ledgergazette.com/2018/04/17/viewray-vray-given-coverage-optimism-score-of-0-06.html.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.